We found that high TNFR3F12A expression or low NR1H3 and ITIH4 expression was positively correlated with paclitaxel sensitivity, indicating that high-risk BLCA patients could benefit from second-line paclitaxel chemotherapy. The gene discussed is ITIH4; the disease is bladder transitional cell carcinoma.